Switch theme
Sign up to access all valuation multiples
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
2003
338
LTM Revenue $57.8M
LTM EBITDA -$213M
-$244M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sutro Biopharma has a last 12-month revenue of $57.8M and a last 12-month EBITDA of -$213M.
In the most recent fiscal year, Sutro Biopharma achieved revenue of $62.0M and an EBITDA of -$187M.
Sutro Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sutro Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $154M | $62.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$58.0M | -$187M | XXX | XXX | XXX |
| EBITDA Margin | -38% | -301% | XXX | XXX | XXX |
| Net Profit | -$119M | -$107M | XXX | XXX | XXX |
| Net Margin | -78% | -172% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sutro Biopharma's stock price is $1.
Sutro Biopharma has current market cap of $50.0M, and EV of -$244M.
See Sutro Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$244M | $50.0M | XXX | XXX | XXX | XXX | $-2.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sutro Biopharma has market cap of $50.0M and EV of -$244M.
Sutro Biopharma's trades at -4.2x LTM EV/Revenue multiple, and 1.1x LTM EBITDA.
Analysts estimate Sutro Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sutro Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$244M | XXX | XXX | XXX |
| EV/Revenue | -3.9x | XXX | XXX | XXX |
| EV/EBITDA | 1.3x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSutro Biopharma's NTM/LTM revenue growth is -16%
Sutro Biopharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Sutro Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sutro Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sutro Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -60% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -301% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 222% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -317% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 78% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 406% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 484% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sutro Biopharma acquired XXX companies to date.
Last acquisition by Sutro Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Sutro Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sutro Biopharma founded? | Sutro Biopharma was founded in 2003. |
| Where is Sutro Biopharma headquartered? | Sutro Biopharma is headquartered in United States of America. |
| How many employees does Sutro Biopharma have? | As of today, Sutro Biopharma has 338 employees. |
| Who is the CEO of Sutro Biopharma? | Sutro Biopharma's CEO is Ms. Jane Chung. |
| Is Sutro Biopharma publicy listed? | Yes, Sutro Biopharma is a public company listed on NAS. |
| What is the stock symbol of Sutro Biopharma? | Sutro Biopharma trades under STRO ticker. |
| When did Sutro Biopharma go public? | Sutro Biopharma went public in 2018. |
| Who are competitors of Sutro Biopharma? | Similar companies to Sutro Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sutro Biopharma? | Sutro Biopharma's current market cap is $50.0M |
| What is the current revenue of Sutro Biopharma? | Sutro Biopharma's last 12-month revenue is $57.8M. |
| What is the current EBITDA of Sutro Biopharma? | Sutro Biopharma's last 12-month EBITDA is -$213M. |
| What is the current EV/Revenue multiple of Sutro Biopharma? | Current revenue multiple of Sutro Biopharma is -4.2x. |
| What is the current EV/EBITDA multiple of Sutro Biopharma? | Current EBITDA multiple of Sutro Biopharma is 1.1x. |
| What is the current revenue growth of Sutro Biopharma? | Sutro Biopharma revenue growth between 2023 and 2024 was -60%. |
| Is Sutro Biopharma profitable? | Yes, Sutro Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
